Lymphoproliferative Disorders (Lymphoproliferative Disorder) Summary

Networked: 3477 relevant articles (128 outcomes, 203 trials/studies) for this Disease

Key Drugs and Agents for Lymphoproliferative Disorders

1. rituximab (Mabthera) : 28 outcomes 15 studies in 166 results : FDA 3
   
2. Methotrexate (Mexate) : 10 outcomes 3 studies in 89 results : FDA 8 Generic
   
3. purine : 5 outcomes 1 study in 35 results : IBA
   
4. Cyclophosphamide (Cytoxan) : 4 outcomes 3 studies in 27 results : FDA 10 Generic
   
5. Etoposide (VP 16) : 4 outcomes in 6 results : FDA 16 Generic
   
6. fludarabine : 3 outcomes 5 studies in 49 results : IBA
   
7. Monoclonal Antibodies : 3 outcomes 4 studies in 36 results : IBA
   
8. Cladribine : 3 outcomes 3 studies in 32 results : FDA 3 Generic
   
9. alemtuzumab (Campath) : 3 outcomes 2 studies in 25 results : FDA 2
   
10. Sirolimus (Rapamycin) : 3 outcomes in 11 results : FDA 2
    

Diseases Related to Lymphoproliferative Disorders

1. B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
2. Rheumatoid Arthritis
3. Infection
4. Lymphoma (Lymphomas)
5. Non-Hodgkin Lymphoma (Lymphosarcoma)

Key Therapies for Lymphoproliferative Disorders

1. Transplants (Transplant) : 28 outcomes 48 studies in 1141 results
   
2. Transplantation (Transplant Recipients) : 15 outcomes 28 studies in 527 results
   
3. Drug Therapy (Chemotherapy) : 13 outcomes 4 studies in 97 results
   
4. Organ Transplantation : 5 outcomes 6 studies in 226 results
   
5. Kidney Transplantation : 3 outcomes 7 studies in 95 results